Published in JAMA on January 23, 2008
Atkins Diet and Prostate Cancer Clinical Trial | NCT00932672
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys (2014) 2.21
Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev (2008) 2.20
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol (2009) 2.18
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology (2013) 2.08
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc (2008) 2.01
Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst (2010) 1.63
Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer (2011) 1.62
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol (2015) 1.55
Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol (2016) 1.49
Diffusion-weighted MRI in early assessment of tumour response to radiotherapy in high-risk prostate cancer. Br J Radiol (2014) 1.47
Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int (2011) 1.46
Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol (2016) 1.45
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol (2016) 1.45
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer (2012) 1.27
Radiotherapy and Hormone Treatment in Prostate Cancer. Dtsch Arztebl Int (2016) 1.21
Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol (2009) 1.21
The German S3 guideline prostate cancer: aspects for the radiation oncologist. Strahlenther Onkol (2010) 1.09
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst (2012) 1.07
Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol (2014) 1.06
Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann Oncol (2012) 1.04
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer (2011) 1.00
Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med (2011) 1.00
Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol (2010) 1.00
Potential stages for prostate cancer prevention with selenium: implications for cancer survivors. Cancer Res (2009) 0.97
Cardiac and cognitive effects of androgen deprivation therapy: are they real? Curr Oncol (2010) 0.95
Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Radiat Oncol (2012) 0.95
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer (2010) 0.94
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer (2009) 0.93
Management of high-risk localized prostate cancer. Adv Urol (2011) 0.93
Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc Patient Saf (2011) 0.92
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci (2013) 0.89
Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2012) 0.86
Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol (2010) 0.85
All-cause mortality as an outcome in epidemiologic studies: proceed with caution. Eur J Epidemiol (2014) 0.85
Tissue biomarkers for prostate cancer radiation therapy. Curr Mol Med (2012) 0.84
The genetics of castration-resistant prostate cancer: what can the germline tell us? Clin Cancer Res (2008) 0.84
Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2011) 0.84
Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. J Urol (2015) 0.84
Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol (2010) 0.82
The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. J Cancer Res Clin Oncol (2015) 0.82
Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate. J Oncol (2014) 0.81
Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art. Cancer Manag Res (2010) 0.81
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival. Transl Oncol (2015) 0.81
Serially heterotransplanted human prostate tumours as an experimental model. J Cell Mol Med (2009) 0.80
Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis. J Contemp Brachytherapy (2013) 0.80
Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer (2014) 0.80
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Front Oncol (2016) 0.79
Hormone therapy in the management of prostate cancer: evidence-based approaches. Ther Adv Urol (2010) 0.79
Saudi Oncology Society clinical management guidelines for prostate cancer. Urol Ann (2011) 0.78
Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients? Contemp Oncol (Pozn) (2015) 0.78
Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy. World J Radiol (2015) 0.78
Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer. Oncol Lett (2015) 0.77
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer (2014) 0.77
Challenges of managing elderly men with prostate cancer. Nat Rev Clin Oncol (2014) 0.77
Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis. Br J Cancer (2014) 0.77
Testosterone replacement and prostate cancer. Indian J Urol (2012) 0.76
The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study. Support Care Cancer (2014) 0.75
Radical radiotherapy for high-risk prostate cancer in older men. Oncologist (2012) 0.75
The relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancer. J Geriatr Oncol (2013) 0.75
Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma. Prostate Cancer (2016) 0.75
The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer. Prostate Cancer (2012) 0.75
Comparisons of oncological and functional outcomes among radical retropubic prostatectomy, high dose rate brachytherapy, cryoablation and high-intensity focused ultrasound for localized prostate cancer. Springerplus (2016) 0.75
Fortifying the Treatment of Prostate Cancer with Physical Activity. Prostate Cancer (2016) 0.75
Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer (2014) 0.75
Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Open Access J Urol (2011) 0.75
Primary radiotherapy vs conservative management for localized prostate cancer-a population-based study. Prostate Cancer Prostatic Dis (2015) 0.75
The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer. Prostate Cancer Prostatic Dis (2017) 0.75
Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trial. Prostate Cancer (2014) 0.75
High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol (2015) 0.75
Prostate cancer: Cardiac mortality associated with ADT plus radiotherapy. Nat Rev Urol (2015) 0.75
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. Urol Ann (2016) 0.75
Targeted therapies: An important piece of the localized prostate cancer puzzle? Nat Rev Clin Oncol (2011) 0.75
Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence. Ther Adv Urol (2017) 0.75
Physical functioning for prostate health. Can Urol Assoc J (2014) 0.75
The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation. BMC Cancer (2015) 0.75
Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy. Radiat Oncol (2016) 0.75
Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value >40 ng/ml. Rep Pract Oncol Radiother (2012) 0.75
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. Urol Ann (2014) 0.75
Weighing the risks: prostate cancer versus cardiovascular disease. Rev Urol (2008) 0.75
Radiation treatment for patients with intermediate-risk prostate cancer. Ther Adv Urol (2012) 0.75
Carbogen gas and radiotherapy outcomes in prostate cancer. Ther Adv Urol (2013) 0.75
The potential impact of adding genetic markers to clinical parameters in managing high-risk prostate cancer patients. Springerplus (2013) 0.75
Advances and future directions in management of prostate cancer. Indian J Surg (2010) 0.75
Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer. Curr Treat Options Cardiovasc Med (2017) 0.75
Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. World J Urol (2016) 0.75
Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model. Int J Nanomedicine (2017) 0.75
Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy. Prostate Cancer Prostatic Dis (2017) 0.75
Prognostic value of saturated prostate cryoablation for localized prostate cancer. World J Urol (2015) 0.75
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Improving marginal likelihood estimation for Bayesian phylogenetic model selection. Syst Biol (2010) 4.32
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol (2011) 3.48
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA (2005) 2.85
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol (2008) 2.31
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol (2006) 2.29
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol (2012) 2.24
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int (2013) 2.18
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer (2013) 2.10
Chemotherapy for teratoma with malignant transformation. J Clin Oncol (2003) 2.06
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Missing data in clinical studies: issues and methods. J Clin Oncol (2012) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol (2002) 2.01
Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center and the Association of Directors of Anatomic and Surgical Pathology. Arch Pathol Lab Med (2015) 2.01
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys (2013) 2.00
Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res (2003) 1.99
Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res (2005) 1.98
Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol (2005) 1.98
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila) (2010) 1.92
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol (2009) 1.91
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.84
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A (2005) 1.80
Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev (2005) 1.80
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2011) 1.77
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer (2007) 1.70
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68
Choosing among partition models in Bayesian phylogenetics. Mol Biol Evol (2010) 1.66
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer (2008) 1.65
Bayesian analysis for generalized linear models with nonignorably missing covariates. Biometrics (2005) 1.65
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol (2008) 1.62
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res (2005) 1.61
PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA (2007) 1.61
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol (2011) 1.58
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer (2014) 1.58